Literature DB >> 25833323

Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.

Juling Ji1,2, Tobias Eggert3, Anuradha Budhu1, Marshonna Forgues1, Atsushi Takai1, Hien Dang1, Qinghai Ye4, Ju-Seog Lee5, Ji Hoon Kim6, Tim F Greten3, Xin Wei Wang1.   

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) patients suffer from a poor survival rate and a high incidence of postoperative recurrence. The hepatic microenvironment plays a significant role in the initiation, progression, and recurrence of HCC; however, the causal mechanisms of these phenomena are unclear. Given the predominant underlying fibrotic and cirrhotic conditions of the liver prone to HCC and its recurrence, alterations of components of the inflammatory milieu have been suggested as factors that promote HCC development. In particular, activated hepatic stellate cells (A-HSCs), which play a key role in liver fibrosis and cirrhosis, have been suggested as contributors to the HCC-prone microenvironment. Here, we have identified and validated an A-HSC-specific gene expression signature among nontumor tissues of 319 HCC patients that is significantly and independently associated with HCC recurrence and survival. Peritumoral, rather than tumor tissue-related, A-HSC-specific gene expression is associated with recurrence and poor survival. Analyses of A-HSC-specific gene signatures and further immunohistochemical validation in an additional 143 HCC patients have revealed that A-HSCs preferentially affect monocyte populations, shifting their gene expression from an inflammatory to an immunosuppressive signature. In addition, the interaction between A-HSCs and monocytes induces protumorigenic and progressive features of HCC cells by enhancing cell migration and tumor sphere formation.
CONCLUSION: A-HSCs play a significant role in promoting HCC progression through interaction with and alteration of monocyte activities within the liver microenvironment; thus, disrupting the interactions and signaling events between the inflammatory milieu and components of the microenvironment may be useful therapeutic strategies for preventing HCC tumor relapse.
© 2015 by the American Association for the Study of Liver Diseases. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25833323      PMCID: PMC4515211          DOI: 10.1002/hep.27822

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

1.  Comparative proteomic analysis of rat hepatic stellate cell activation: a comprehensive view and suppressed immune response.

Authors:  Juling Ji; Feng Yu; Qiuhong Ji; Zhiyao Li; Kuidong Wang; Jinsheng Zhang; Jinbiao Lu; Li Chen; Qun E; Yaoying Zeng; Yuhua Ji
Journal:  Hepatology       Date:  2012-06-06       Impact factor: 17.425

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection.

Authors:  Min-Jie Ju; Shuang-Jian Qiu; Jia Fan; Yong-Sheng Xiao; Qiang Gao; Jian Zhou; Yi-Wei Li; Zhao-You Tang
Journal:  Am J Clin Pathol       Date:  2009-04       Impact factor: 2.493

4.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Authors:  Stephanie Roessler; Hu-Liang Jia; Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Ju-Seog Lee; Snorri S Thorgeirsson; Zhongtang Sun; Zhao-You Tang; Lun-Xiu Qin; Xin Wei Wang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

5.  Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins.

Authors:  Linda Wang; Esther W Y Chang; Siew Cheng Wong; Siew-Min Ong; Debra Q Y Chong; Khoon Lin Ling
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

6.  Gene expression profiles during hepatic stellate cell activation in culture and in vivo.

Authors:  Samuele De Minicis; Ekihiro Seki; Hiroshi Uchinami; Johannes Kluwe; Yonghui Zhang; David A Brenner; Robert F Schwabe
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

7.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

8.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

9.  Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.

Authors:  Hirohisa Okabe; Toru Beppu; Hiromitsu Hayashi; Kei Horino; Toshiro Masuda; Hiroyuki Komori; Shinji Ishikawa; Masayuki Watanabe; Hiroshi Takamori; Ken-ichi Iyama; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2009-06-23       Impact factor: 5.344

Review 10.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03
View more
  60 in total

Review 1.  Myeloid Cells and Chronic Liver Disease: a Comprehensive Review.

Authors:  Min Lian; Carlo Selmi; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 2.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

3.  Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation.

Authors:  Qing-Qi Ren; Shun-Jun Fu; Qiang Zhao; Zhi-Yong Guo; Fei Ji; Mao-Gen Chen; Lin-Wei Wu; Xiao-Shun He
Journal:  Tumour Biol       Date:  2016-01-12

4.  Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma.

Authors:  Sergio A Gradilone
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

5.  Tumour-activated liver stromal cells regulate myeloid-derived suppressor cells accumulation in the liver.

Authors:  H Zhang; G He; Y Kong; Y Chen; B Wang; X Sun; B Jia; X Xie; X Wang; D Chen; L Wei; M Zhang; H Zeng; H Chen
Journal:  Clin Exp Immunol       Date:  2017-02-07       Impact factor: 4.330

Review 6.  Molecular prognostic prediction in liver cirrhosis.

Authors:  Nicolas Goossens; Shigeki Nakagawa; Yujin Hoshida
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 7.  Tumor regulation of the tissue environment in the liver.

Authors:  Tobias Eggert; Tim F Greten
Journal:  Pharmacol Ther       Date:  2017-02-04       Impact factor: 12.310

8.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

Review 9.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

10.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.